Short answer, as of October 27, 2026: none of the six under review. On 30 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A Bulks List. A recommendation is not an approval, and the FDA had not begun formal rulemaking. Anyone telling you otherwise is ahead of the record.
The July 2026 vote
| Peptide | FDA status | Committee vote |
|---|---|---|
| BPC-157 Synthetic pentadecapeptide (gastric-derived) | Not FDA-approved | Recommended 30 Jul 2026 |
| Epitalon Pineal tetrapeptide (Ala-Glu-Asp-Gly) | Not FDA-approved | Recommended 30 Jul 2026 |
| KPV Anti-inflammatory tripeptide | Not FDA-approved | Recommended 30 Jul 2026 |
| MOTS-c Mitochondrial-derived peptide | Not FDA-approved | Recommended 30 Jul 2026 |
| Semax Nootropic peptide (ACTH(4-10) analog) | Not FDA-approved | Recommended 30 Jul 2026 |
| TB-500 Synthetic Tβ4 fragment | Not FDA-approved | Recommended 30 Jul 2026 |
Questions
No. It was recommended by FDA's Pharmacy Compounding Advisory Committee on 30 July 2026, but a recommendation is not an approval. On 30 October 2026 HHS published a notice of availability for a DRAFT interim enforcement discretion policy on 503A compounding using certain peptide bulk drug substances (Federal Register, Docket HHS-OASH-2026-0496), open for comment for two weeks. A draft interim enforcement policy is not FDA approval.
Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500. Emideltide was reviewed and not recommended.
Formal FDA rulemaking after a committee recommendation typically runs 8 to 24 months. Nothing changes legally until it completes.
Every one with its regulatory status read off FDA label data, and its sources listed.
Open the libraryEducational reference only. This page reports the regulatory record. It is not legal advice, not medical advice, and carries no dosing information. OPTML does not offer or supply the compounds under review.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.